152 related articles for article (PubMed ID: 15270795)
1. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795
[TBL] [Abstract][Full Text] [Related]
2. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
3. The collaborative atorvastatin diabetes study: preliminary results.
Owen OG
Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
[TBL] [Abstract][Full Text] [Related]
4. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Velussi M
Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
[TBL] [Abstract][Full Text] [Related]
5. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Neil HA; DeMicco DA; Luo D; Betteridge DJ; Colhoun HM; Durrington PN; Livingstone SJ; Fuller JH; Hitman GA;
Diabetes Care; 2006 Nov; 29(11):2378-84. PubMed ID: 17065671
[TBL] [Abstract][Full Text] [Related]
6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
[TBL] [Abstract][Full Text] [Related]
8. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
9. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Wolffenbuttel BH; Franken AA; Vincent HH;
J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557
[TBL] [Abstract][Full Text] [Related]
12. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
Shimabukuro M; Higa M; Tanaka H; Shimabukuro T; Yamakawa K; Masuzaki H
Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
[TBL] [Abstract][Full Text] [Related]
13. Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting.
Sathyapalan T; Atkin SL; Kilpatrick ES
Diabet Med; 2008 Aug; 25(8):909-15. PubMed ID: 18959603
[TBL] [Abstract][Full Text] [Related]
14. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Palmer G;
Am J Cardiol; 2004 Sep; 94(6):720-4. PubMed ID: 15374773
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Constance C; Westphal S; Chung N; Lund M; McCrary Sisk C; Johnson-Levonas AO; Massaad R; Allen C
Diabetes Obes Metab; 2007 Jul; 9(4):575-84. PubMed ID: 17451425
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
17. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
Colhoun HM; Thomason MJ; Mackness MI; Maton SM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
Diabet Med; 2002 Mar; 19(3):201-11. PubMed ID: 11918622
[TBL] [Abstract][Full Text] [Related]
18. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
Holmberg B; Brännström M; Bucht B; Crougneau V; Dimeny E; Ekspong A; Granroth B; Gröntoft KC; Hadimeri H; Ingman B; Isaksson B; Johansson G; Lindberger K; Lundberg L; Mikaelsson L; Olausson E; Persson B; Welin D; Wikdahl AM; Stegmayr BG
Scand J Urol Nephrol; 2005; 39(6):503-10. PubMed ID: 16303728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
